| FAZIO, Nicola, Jean-Francois MARTINI, Adina E. CROITORU, Michael SCHENKER, Sherry LI, Brad ROSBROOK, Kathrine FERNANDEZ, Jiří TOMÁŠEK, Espen THIIS-EVENSEN, Matthew KULKE a Eric RAYMOND. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. Future Oncology. London: Future Medicine Ltd., 2019, roč. 15, č. 17, s. 1997-2007. ISSN 1479-6694. Dostupné z: https://dx.doi.org/10.2217/fon-2018-0934. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1615257,
author = {Fazio, Nicola and Martini, JeanandFrancois and Croitoru, Adina E. and Schenker, Michael and Li, Sherry and Rosbrook, Brad and Fernandez, Kathrine and Tomášek, Jiří and ThiisandEvensen, Espen and Kulke, Matthew and Raymond, Eric},
article_location = {London},
article_number = {17},
doi = {http://dx.doi.org/10.2217/fon-2018-0934},
keywords = {biomarkers; efficacy; pancreatic neuroendocrine tumor; sunitinib; VEGF},
language = {eng},
issn = {1479-6694},
journal = {Future Oncology},
title = {Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors},
url = {http://dx.doi.org/10.2217/fon-2018-0934},
volume = {15},
year = {2019}
}
TY - JOUR
ID - 1615257
AU - Fazio, Nicola - Martini, Jean-Francois - Croitoru, Adina E. - Schenker, Michael - Li, Sherry - Rosbrook, Brad - Fernandez, Kathrine - Tomášek, Jiří - Thiis-Evensen, Espen - Kulke, Matthew - Raymond, Eric
PY - 2019
TI - Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
JF - Future Oncology
VL - 15
IS - 17
SP - 1997-2007
EP - 1997-2007
PB - Future Medicine Ltd.
SN - 14796694
KW - biomarkers
KW - efficacy
KW - pancreatic neuroendocrine tumor
KW - sunitinib
KW - VEGF
UR - http://dx.doi.org/10.2217/fon-2018-0934
L2 - http://dx.doi.org/10.2217/fon-2018-0934
N2 - Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.
ER -
FAZIO, Nicola, Jean-Francois MARTINI, Adina E. CROITORU, Michael SCHENKER, Sherry LI, Brad ROSBROOK, Kathrine FERNANDEZ, Jiří TOMÁŠEK, Espen THIIS-EVENSEN, Matthew KULKE a Eric RAYMOND. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. \textit{Future Oncology}. London: Future Medicine Ltd., 2019, roč.~15, č.~17, s.~1997-2007. ISSN~1479-6694. Dostupné z: https://dx.doi.org/10.2217/fon-2018-0934.
|
